NewsMarkets

Business

Walmart Expands No-Cost Drug Coverage to Include Ozempic and Mounjaro

The retailer adds over 250 medications, including diabetes drugs, to its no-cost list for frontline workers starting in the new year.

4 publishers · 5 articles · first seen 13 Oct 2026 · updated 24d ago

Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made

First reported by Quartz, 3h 11m ahead of the next publisher · who breaks stories first

This story has stopped developing; this page is its permanent record. More from that day

The story so far

4 publishers have covered this in 5 articles since 13 Oct 2026. Quartz published first, on 13 October at 13:50 UTC; All Content from Business Insider followed 3h 12m later. The most recent article, from Inc., appeared on 14 October at 12:13 UTC.

Outlets reporting it: CNBC (major outlet), Quartz, All Content from Business Insider, Inc..

No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.

Sources

Every article we clustered into this story. Headlines link to the publisher.

  1. Walmart to cover some GLP-1s, inhalers and insulin for employees at no cost as it expands benefits CNBC ·
  2. Walmart is Covering Ozempic and Mounjaro for Employees, but Not for Weight Loss Inc.
  3. Walmart US workers are getting some new health care benefits in the new year All Content from Business Insider
  4. Walmart plant, über 250 Medikamente, darunter einige Diabetesmedikamente, für Mitarbeiter kostenlos abzudecken. Quartz
  5. Walmart plans to cover 250+ drugs, including some diabetes medications, at no cost for employees Quartz

In this story

  • Walmart
  • Ozempic
  • Mounjaro
Embed this story

Paste this into any web page to show the live odds, with a link back here.